Company intelligence / Profile preview

Dynamix Pharmaceuticals

Ownership: Private
Development stage: Preclinical

Overview

Dynamix has developed a pipeline of novel small-molecule drugs targeting cancer and autoimmune indications using its proprietary DynamixFit™ platform. Lead programs include dual mechanism SYK/JAK inhibitors for autoimmune disease and several targeted therapies for cancer metabolism and signaling pathways. Most assets are currently in preclinical development, with at least one program advancing toward clinical proof-of-concept.

Therapeutic areas: OncologyImmunologyHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

8 assets

DNX-04042

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

– CleveXel Pharma – partnership to develop an oral dual-mechanism SYK/JAK inhibitor for rheumatoid arthritis.

Beyond the preview

Go deeper on Dynamix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamix Pharmaceuticals.

Explore the full profile